
Identifying which patients should receive which therapy for lung cancer
Keith Kerr

Next steps for the CONVERT trial in LS-SCLC
Corinne Faivre-Finn

Lung cancer immunotherapy: the need for predictive biomarkers
James Spicer

Biomarker guidelines for non-small cell lung cancer
Keith Kerr

Clinical implications of CTCs in prostate cancer – are they the best thing to measure?
Susanne Osanto